Phase III Success For Roche’s Crovalimab In Crowded PNH Market
But AstraZeneca Expected To Retain Grip In The Space
Executive Summary
Roche is looking to challenge AstraZeneca's dominance in PNH with its subcutaneously administered once-a-month treatment but could struggle to rival the company's and Novartis’s oral therapy.
You may also be interested in...
Apellis Set For Blockbuster Success With Syfovre, The First Approved Geographic Atrophy Drug
Around five million people worldwide suffer from geographic atrophy, and Apellis’s drug will be the first to offer hope of slowing the disease’s progress, as it reaches the US market at a price comparable to the VEGF inhibitors.
Novartis Excited About Iptacopan But Downcast After Huntington’s Blow
The Swiss major is close to its first submission for ‘pipeline in a pill’ iptacopan but has conceded defeat with branaplam as a potential treatment for Huntington’s disease.
Continuity Or Change? Roche’s New CEO And Pharma Leader Take On Big Strategy Question
Roche will suffer a hangover from its COVID-19 successes this year as revenues stagnate and its future strategy is yet to be laid out by incoming CEO Thomas Schinecker.